C4 Therapeutics, Inc logo

CCCC

C4 Therapeutics, Inc

$7.41

Earnings Summary

Revenue
$3.26Mn
Net Profits
$-34.75Mn
Net Profit Margins
-1065.75%

Highlights

Revenue:

C4 Therapeutics, Inc’s revenue jumped 14.26% since last year same period to $3.26Mn in the Q4 2023. On a quarterly growth basis, C4 Therapeutics, Inc has generated -70.55% fall in its revenue since last 3-months.

Net Profits:

C4 Therapeutics, Inc’s net profit jumped 3.67% since last year same period to $-34.75Mn in the Q4 2023. On a quarterly growth basis, C4 Therapeutics, Inc has generated -28.54% fall in its net profits since last 3-months.

Net Profit Margins:

C4 Therapeutics, Inc’s net profit margin jumped 15.69% since last year same period to -1065.75% in the Q4 2023. On a quarterly growth basis, C4 Therapeutics, Inc has generated -336.44% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the C4 Therapeutics, Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.35
EPS Estimate Current Year
-0.35

Highlights

EPS Estimate Current Quarter:

C4 Therapeutics, Inc’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a 48.53% jump from last quarter’s estimates.

EPS Estimate Current Year:

C4 Therapeutics, Inc’s earning per share (EPS) estimates for the current year stand at -0.35.

Key Ratios

Key ratios of the C4 Therapeutics, Inc post its Q4 2023 earnings

Earning Per Share (EPS)
-0.7
Return on Assets (ROA)
-0.22
Return on Equity (ROE)
-0.5

Highlights

Earning Per Share (EPS):

C4 Therapeutics, Inc’s earning per share (EPS) jumped 9.09% since last year same period to -0.7 in the Q4 2023. This indicates that the C4 Therapeutics, Inc has generated 9.09% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. C4 Therapeutics, Inc’s return on assets (ROA) stands at -0.22.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. C4 Therapeutics, Inc’s return on equity (ROE) stands at -0.5.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-02-22
-0.68
-0.7
-2.94%
2023-11-01
-0.66
-0.52
21.21%
2023-08-08
-0.69
-0.73
-5.8%
2023-05-04
-0.75
-0.71
5.33%